Nature Communications (May 2016)
miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint
- Shaohua Xu,
- Zhen Tao,
- Bo Hai,
- Huagen Liang,
- Ying Shi,
- Tao Wang,
- Wen Song,
- Yong Chen,
- Jun OuYang,
- Jinhong Chen,
- Fanfei Kong,
- Yishan Dong,
- Shi-Wen Jiang,
- Weiyong Li,
- Ping Wang,
- Zhiyong Yuan,
- Xiaoping Wan,
- Chenguang Wang,
- Wencheng Li,
- Xiaoping Zhang,
- Ke Chen
Affiliations
- Shaohua Xu
- Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine
- Zhen Tao
- Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer institute & Hospital, National Clinical Research Center of Cancer
- Bo Hai
- Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Huagen Liang
- Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Ying Shi
- Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Tao Wang
- Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Wen Song
- Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Yong Chen
- Emergency Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Jun OuYang
- Department of Gynecology, Changzhou Maternal and Child Health Hospital Affiliated to Nanjing Medical University
- Jinhong Chen
- Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine
- Fanfei Kong
- Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine
- Yishan Dong
- Department of Gynecology, Changzhou Maternal and Child Health Hospital Affiliated to Nanjing Medical University
- Shi-Wen Jiang
- Department of Biomedical Science, Mercer University School of Medicine
- Weiyong Li
- Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Ping Wang
- Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer institute & Hospital, National Clinical Research Center of Cancer
- Zhiyong Yuan
- Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer institute & Hospital, National Clinical Research Center of Cancer
- Xiaoping Wan
- Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine
- Chenguang Wang
- Key Laboratory of Tianjin Radiation and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences
- Wencheng Li
- Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Xiaoping Zhang
- Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Ke Chen
- Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- DOI
- https://doi.org/10.1038/ncomms11406
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 13
Abstract
Resistance to chemotherapy occurs in many ovarian cancer cases. Here, the authors show that mir-424(322) expression restores the sensitivity of ovarian cancer cells to chemotherapy by blocking the PD-L1 immune checkpoint, and find that combining immunotherapy and chemotherapy has a synergistic effect.
